Ellsworth Advisors LLC Makes New $900,000 Investment in OrthoPediatrics Corp. $KIDS

Ellsworth Advisors LLC purchased a new position in OrthoPediatrics Corp. (NASDAQ:KIDS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,422 shares of the company’s stock, valued at approximately $900,000. Ellsworth Advisors LLC owned approximately 0.15% of OrthoPediatrics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of OrthoPediatrics during the second quarter valued at approximately $24,347,000. AIGH Capital Management LLC acquired a new stake in OrthoPediatrics in the second quarter worth approximately $5,161,000. Nantahala Capital Management LLC acquired a new stake in OrthoPediatrics in the second quarter worth approximately $4,636,002. AWM Investment Company Inc. bought a new position in OrthoPediatrics during the 2nd quarter valued at $4,537,000. Finally, Granahan Investment Management LLC increased its position in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after purchasing an additional 232,760 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Trading Up 1.4%

Shares of OrthoPediatrics stock opened at $22.57 on Friday. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The business has a fifty day simple moving average of $23.10 and a 200-day simple moving average of $19.91.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, major shareholder Squadron Capital Llc sold 326,700 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. This represents a 4.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Jennifer Pritzker sold 326,700 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the transaction, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. This represents a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. Corporate insiders own 32.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on KIDS. Needham & Company LLC upped their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research reaffirmed a “buy” rating and issued a $29.00 price objective on shares of OrthoPediatrics in a research note on Monday, September 14th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Truist Financial raised shares of OrthoPediatrics to a “hold” rating in a research note on Thursday, October 1st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. Headquartered in Warsaw, Indiana, the company designs implants and instruments intended to address the distinct anatomical and clinical needs of pediatric patients, including those whose bones are still growing.

Its product portfolio includes systems for pediatric trauma and deformity correction, scoliosis treatment, limb reconstruction, and pediatric sports medicine.